Population Attributable Fraction of Diabetes on the Risk of Gastrointestinal Cancers: Overall and by Specific Cancer Sites in a Cohort Study.

IF 3.4 3区 医学 Q2 ONCOLOGY Cancer Epidemiology Biomarkers & Prevention Pub Date : 2025-06-03 DOI:10.1158/1055-9965.EPI-24-1632
Shu-Lin Chuang, Teresa Cheng-Chieh Chu, Yi-Chen Juan, Ting-Chuan Wang, Yen-Yun Yang, Ting-Ann Wang, Ying-Ting Chao, Pei-Ju Lin, Yu-Cih Yang, Yu-Chun Wang, Chu-Lin Tsai, Wei-Shiung Yang, Yi-Chia Lee, Chi-Ling Chen
{"title":"Population Attributable Fraction of Diabetes on the Risk of Gastrointestinal Cancers: Overall and by Specific Cancer Sites in a Cohort Study.","authors":"Shu-Lin Chuang, Teresa Cheng-Chieh Chu, Yi-Chen Juan, Ting-Chuan Wang, Yen-Yun Yang, Ting-Ann Wang, Ying-Ting Chao, Pei-Ju Lin, Yu-Cih Yang, Yu-Chun Wang, Chu-Lin Tsai, Wei-Shiung Yang, Yi-Chia Lee, Chi-Ling Chen","doi":"10.1158/1055-9965.EPI-24-1632","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aims to assess the population attributable fraction (PAF) of diabetes on the gastrointestinal cancers overall and by specific cancer sites.</p><p><strong>Methods: </strong>This study analyzed healthcare data from Taiwan (2006-2019) for 2,362,587 patients with and without diabetes. Gastrointestinal cancers were identified via cancer registry data. Poisson regression calculated incidence rate ratios (IRR) and 95% confidence intervals (CI), with propensity score-matched patients without diabetes as the reference. PAFs estimated cancer incidence attributable to diabetes by sites.</p><p><strong>Results: </strong>80,186 patients with diabetes (mean age, 63.3 years; 47.3% women) were matched with 152,323 patients without diabetes (62.7 years; 48.0% women). By the end of 2021, 2,659 of 80,186 patients with diabetes (incidence rate: 3.89 per 1,000 person-years) developed gastrointestinal cancers compared with 4,150 of 152,323 (incidence rate: 3.04 per 1,000 person-years) patients without diabetes. Diabetes was associated with a higher risk of gastrointestinal cancers (adjusted IRR of 1.24, 95% CI, 1.18-1.30; PAF: 4.4%, 95% CI, 3.1%-5.8%). The increased risk was primarily driven by pancreatic cancer (adjusted IRR: 1.77, 95% CI, 1.51-2.09; PAF: 12.9%, 95% CI, 7.9%-18.6%) and colorectal cancer (adjusted IRR: 1.28, 95% CI, 1.17-1.39; PAF: 5.1%, 95% CI, 3.0%-7.5%), with a borderline association for liver cancer (adjusted IRR: 1.08, 95% CI, 1.00-1.17; PAF: 1.5%, 95% CI, -0.3% to 3.5%).</p><p><strong>Conclusions: </strong>Diabetes is associated with an increased risk of overall gastrointestinal cancers, largely attributable to pancreatic and colorectal cancers.</p><p><strong>Impact: </strong>Integrating cancer prevention into the objectives of optimal diabetes management is important, especially for cancers with limited screening options.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1007-1015"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology Biomarkers & Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-24-1632","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aims to assess the population attributable fraction (PAF) of diabetes on the gastrointestinal cancers overall and by specific cancer sites.

Methods: This study analyzed healthcare data from Taiwan (2006-2019) for 2,362,587 patients with and without diabetes. Gastrointestinal cancers were identified via cancer registry data. Poisson regression calculated incidence rate ratios (IRR) and 95% confidence intervals (CI), with propensity score-matched patients without diabetes as the reference. PAFs estimated cancer incidence attributable to diabetes by sites.

Results: 80,186 patients with diabetes (mean age, 63.3 years; 47.3% women) were matched with 152,323 patients without diabetes (62.7 years; 48.0% women). By the end of 2021, 2,659 of 80,186 patients with diabetes (incidence rate: 3.89 per 1,000 person-years) developed gastrointestinal cancers compared with 4,150 of 152,323 (incidence rate: 3.04 per 1,000 person-years) patients without diabetes. Diabetes was associated with a higher risk of gastrointestinal cancers (adjusted IRR of 1.24, 95% CI, 1.18-1.30; PAF: 4.4%, 95% CI, 3.1%-5.8%). The increased risk was primarily driven by pancreatic cancer (adjusted IRR: 1.77, 95% CI, 1.51-2.09; PAF: 12.9%, 95% CI, 7.9%-18.6%) and colorectal cancer (adjusted IRR: 1.28, 95% CI, 1.17-1.39; PAF: 5.1%, 95% CI, 3.0%-7.5%), with a borderline association for liver cancer (adjusted IRR: 1.08, 95% CI, 1.00-1.17; PAF: 1.5%, 95% CI, -0.3% to 3.5%).

Conclusions: Diabetes is associated with an increased risk of overall gastrointestinal cancers, largely attributable to pancreatic and colorectal cancers.

Impact: Integrating cancer prevention into the objectives of optimal diabetes management is important, especially for cancers with limited screening options.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
糖尿病对胃肠道癌症风险的人群归因比例:一项队列研究的总体和特定癌症部位
背景:本研究旨在评估糖尿病对胃肠道癌症的总体和特定癌症部位的人口归因分数(PAF)。方法:本研究分析了台湾2006-2019年2,362,587例糖尿病和非糖尿病患者的医疗数据。通过癌症登记数据确定胃肠道癌症。泊松回归计算发病率比(IRRs)和95%置信区间(CIs),以倾向评分匹配的无糖尿病患者为参考。人群归因分数(Population attribution fractions, PAFs)按部位估计糖尿病的癌症发病率。结果:糖尿病患者80186例,平均年龄63.3岁;47.3%的女性)与152,323名无糖尿病患者(62.7岁;48.0%的女性)。到2021年底,80186名糖尿病患者中有2659人(发病率:3.89 / 1000人年)患上了胃肠道癌症,而152323名非糖尿病患者中有4150人(发病率:3.04 / 1000人年)患上了胃肠道癌症。糖尿病与较高的胃肠道癌症风险相关(调整IRR为1.24,95%CI: 1.18-1.30;Paf: 4.4%, 95%ci: 3.1%-5.8%)。增加的风险主要由胰腺癌驱动(调整IRR: 1.77, 95%CI: 1.51-2.09;PAF: 12.9%, 95%CI: 7.9%-18.6%)和结直肠癌(调整IRR: 1.28, 95%CI: 1.17-1.39;PAF: 5.1%, 95%CI: 3.0%-7.5%),与肝癌有临界相关性(校正IRR: 1.08, 95%CI: 1.00-1.17;Paf: 1.5%, 95%ci: -0.3%-3.5%)。结论:糖尿病与总体胃肠道癌症风险增加相关,主要归因于胰腺癌和结直肠癌。影响:将癌症预防纳入最佳糖尿病管理的目标是重要的,特别是对于筛查选择有限的癌症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Epidemiology Biomarkers & Prevention
Cancer Epidemiology Biomarkers & Prevention 医学-公共卫生、环境卫生与职业卫生
CiteScore
6.50
自引率
2.60%
发文量
538
审稿时长
1.6 months
期刊介绍: Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.
期刊最新文献
Urinary Levels of Endocrine-Disrupting Chemicals and Breast Density in Young Women. Evaluating Efficacy of Cervical HPV-HR DNA Testing as Alternative to PET/CT Imaging for Posttreatment Cancer Surveillance: Retrospective Proof-of-Concept Study. Food Insecurity and Clinical Biomarkers of Inflammation among Cancer Survivors in the All of Us Research Program. Highly Sensitive DNA Testing of Fusobacterium nucleatum in Colorectal Tumors. Rurality of Residence and Distance to Clinic Are Risk Factors for Non-engagement in Childhood Cancer Survivor Care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1